Dec 9, 2025 7:00 am EST Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Nov 17, 2025 7:00 am EST Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Nov 14, 2025 7:00 am EST New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Nov 11, 2025 7:00 am EST Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 3, 2025 4:05 pm EST Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
Oct 26, 2025 3:05 pm EDT New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Oct 24, 2025 4:05 am EDT New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Oct 13, 2025 7:00 am EDT Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
